Bpifrance

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Laurent Arthaud

Managing Director

Marion Aubry

Investment Director

Emmanuel Audouard

Director of Transverse Venture Capital Investments Division

Benoit Barteau Ph.D

Investment Director

Nicolas Berdou

Investment Director, Defense Expert

Clarisse Blandin

Investment Director

Elyssa Maufras du Châtellier

Investment Director

Edouard Combette

Investment Director

Charlotte Corbaz

Investment Drector - Large Venture

Nicolas Dardenne

Senior Investment Director, Normandy (Caen Rouen)

Arnaud Despoisse

Director of Occitanie Participations

Philippe Dutheil

Investment Director

Mailys Ferrere

Director of Large Venture Investments

Romain Fourcade

Investment Director

Paul-Francois Fournier

Executive Director, Innovation Department

Pierre Gillet

Investment Director

Vanessa Giraud

Director of Environmental Impact Funds

Alessandro Gonella

Director

Gwenael Hamon

Investment Director

Laurent Higueret

Senior Investment Director, Healthcare and Life Sciences - Large Venture Fund

Louis Janneau

Investment Director and Fund Manager

Magali Joessel

Director of Funds

So-Yeon Koo

Senior Investment Manager

Jérôme Langlade

Investment Director Aquitaine / Limousin / Poitou-Charentes

Eric Lefebvre

Director

Stephane Lefevre-Sauli

Senior Investment Director

Arnaud Legardeur

Investment Director

Chahra Louafi

Senior Investment Director

Serge Mesguich

Director of FIT

Laure Michel

Investment Director

Louis Molis

Investment Director

Jean-Francois Morin

Investment Director

Sébastien Moynot

Director

Adrien Muller

Investment Director

Adrien Néel

Investment Director

Axel Piriou

Director of Investments

Olivier Rameil

Senior Investment Director / VC seed

Vincent Roque

Director

Thibaut Roulon Ph.D

Investment Director

Gilles Schang

Deputy Managing Director

Bruno Villeneuve

Associate

Jean-Marie Fougeray

Senior Investment Director, Brittany

Past deals in Early Venture Stage

Chipiron

Series A in 2025
Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Versant

Grant in 2025
Tech solution to accelerate biodiversity restoration.

Faume

Series A in 2025
Faume operates a technology and logistics platform designed to support businesses in establishing a circular economy. The platform provides a comprehensive white label solution that includes site design, communication, product photography, and customer service. This integrated operational framework allows brands to effectively manage their secondhand business, helping them to engage new customers while retaining existing ones. By adopting sustainable practices, Faume enables clients to enhance their market presence and increase long-term revenue for both physical and online stores.

Galam Robotics

Series A in 2025
Galam Robotics specializes in modular robotic solutions aimed at enhancing logistics and storage processes. The company develops innovative technology that increases productivity and efficiency in urban logistics and trade environments. By transforming storage capabilities in constrained spaces, Galam Robotics enables clients to optimize their storage capacity while maximizing input and output flows. This approach allows businesses to streamline their operations and improve overall performance in logistics and inventory management.

Mabqi

Grant in 2025
Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

The QA Company

Series A in 2025
The QA Company specializes in AI-driven knowledge management solutions. It develops a question-and-answer platform that streamlines access to internal information, supporting decision-making and enhancing productivity across diverse industries such as HR, project management, legal, and technical documentation. The platform enables businesses to create AI chat assistants for their documents and websites.

Keey Aerogel

Series A in 2025
Keey Aerogel specializes in the production of silica aerogel derived from construction waste using a closed-loop process that recycles carbon dioxide and ethanol. The company focuses on the valorization of silica-containing construction and demolition materials, transforming them into high-value aerogel products. These nanoporous materials are designed to enhance energy efficiency in the construction and refurbishment of buildings, as well as for various industrial applications. By leveraging waste materials, Keey Aerogel aims to contribute to sustainable practices while providing effective thermal insulation solutions in ambient conditions.

Hexana

Grant in 2025
Hexana is a nuclear energy company specializing in small modular reactors (SMRs). It operates sodium-cooled fast neutron reactors, integrated with high-temperature storage systems, to produce flexible electricity and process heat. The company aims to reduce nuclear waste volume through its innovative technology.

AISPRID

Series A in 2025
AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.

Coave Therapeutics

Series A in 2025
Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

NEBULA

Grant in 2024
NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

GAiF Ai

Series A in 2024
GAiF Ai is an online community driving Africa's generative AI revolution.

Biomemory

Series A in 2024
Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Mirabelle

Grant in 2024
Mirabelle is a technology-driven financial services company focused on addressing the financial needs of retirees. It specializes in offering reverse mortgage loans and life annuities, with a commitment to providing secure and informed decision-making processes. The company's core business involves advising on life annuity financing, ensuring retirees have access to guaranteed monthly income supplements, and assisting with senior housing renovations. Mirabelle's mission is to enable retirees and their families to live comfortably and securely in their homes during their golden years.

Lingua Custodia

Grant in 2024
Lingua Custodia SAS is a Fintech company specializing in machine translation solutions tailored for the financial sector. Founded in 2011 and headquartered in Montigny-le-Bretonneux, France, the company initially focused on providing specialized machine translation services. It has since expanded its offerings to include a suite of Natural Language Processing (NLP) applications, such as Speech-to-Text automation, document classification, and data extraction from unstructured documents. Lingua Custodia's platform supports various document types, including fund prospectuses, annual reports, and equity research, enabling financial professionals to streamline their translation processes. The company serves a diverse clientele, including investment houses, banks, and language service providers, delivering superior quality through advanced machine learning algorithms specifically designed for the financial domain. Its innovative technology has received recognition and awards within the industry, underscoring its commitment to enhancing translation efficiency for finance-related documents.

Hub2.Io

Series A in 2024
Hub2.Io is a system for digitizing ongoing transactions. Services like cash out, to pay, manage, and others are offered by them. Connecting businesses to their infrastructure will enable them to accept and process payments quickly and safely.

Meiogenix

Series A in 2024
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

FairCraft

Series A in 2024
FairCraft is a company focused on creating a sustainable alternative to traditional animal leather through innovative synthetic biology and material science techniques. By utilizing cellular culture, tissue engineering, and advanced material science, FairCraft develops lab-grown leather that provides a slaughter-free option for the fashion industry. This approach not only aims to reduce CO2 emissions associated with conventional leather production but also ensures high mechanical strength and durability for consumers. Through its commitment to sustainability and cutting-edge technology, FairCraft is positioned to transform the leather market by offering environmentally friendly solutions.

Interactive Autonomous DYnamic Systems

Grant in 2024
Iadys designs, develops, and delivers robotic and AI innovations aimed at environmental preservation. The company's flagship product, the Jellyfishbot, is a robot that collects floating waste and oil in water bodies and performs underwater measurements. Iadys also offers the Mobile Oil Skimmer, which is used for oil spill response. These products are designed to access and clean hard-to-reach areas, contributing to cleaner and safer aquatic environments.

Fudzs

Grant in 2024
Fudzs is a pioneer in the sustainable bioeconomy, specializing in the development of eco-friendly cell bioproduction processes utilizing advanced bioreactor technology. The company focuses on the mass production of cells through innovative biomaterial engineering combined with cellular science, which enables cost-effective solutions for various industries. Fudzs aims to revolutionize the cultivated meat sector by creating affordable and high-quality meat alternatives, as well as enhancing cell therapies. Its proprietary approach to biomaterials is optimized for cell growth, significantly increasing cell amplification and density in bioreactors, thereby unlocking new market opportunities and promoting a more sustainable future in food production and healthcare.

Beyond Aero

Series A in 2024
Hangarar is an aeronautical services platform based in Brazil that focuses on enhancing general aviation. The company aims to transform the market by providing timely and secure information to pilots, ensuring they have access to organized data whenever needed. By streamlining the booking process through a mobile platform, Hangarar simplifies the logistics of finding and securing aviation services at various destinations, allowing pilots to concentrate on flying.

Beyond Aero

Series A in 2024
Beyond Aero is focused on developing the first electric business aircraft powered by hydrogen propulsion, capable of transporting six passengers over distances of up to 800 nautical miles, significantly surpassing battery-powered alternatives. Established in December 2020, the company is innovating the design of a CS23 aircraft to integrate hydrogen-electric propulsion, emphasizing fuel cell technology, hydrogen tank systems, and advanced cooling mechanisms. With headquarters in Toulouse, Paris, and Los Angeles, Beyond Aero has assembled a team of over 50 skilled engineers from prominent aerospace firms and is actively seeking to expand its workforce. The company has successfully raised over $44 million from various investors and has received $914 million in Letters of Intent for the production of 108 aircraft. Beyond Aero recently achieved a milestone with France's first manned, fully hydrogen-electric flight and is a participant in the World Economic Forum's First Movers Coalition, reflecting its dedication to advancing zero-emission aviation solutions.

Okomera

Grant in 2024
Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Kriptown

Series A in 2024
Kriptown is a financial platform that focuses on financing the development of regional startups and small to medium-sized enterprises (SMEs). It offers a unique opportunity for investors to purchase tokens linked to the value of a company's shares, thereby democratizing access to fundraising. By utilizing advanced technology and a creative strategy, Kriptown streamlines equity funding through a transparent process that includes standardized whitepapers for each investment opportunity. This ensures that investors have comprehensive information before making any commitments. Additionally, members can contribute digital assets, which may be stored, utilized, or exchanged on Kriptown's secondary market. The company emphasizes customer satisfaction and innovation, making investment in startups more accessible to a broad and diverse range of investors.

VELA

Series A in 2024
VELA is an innovative 100% wind-powered maritime transport. It has been working to address the climate emergency by providing a creative, sustainable, and socially responsible maritime transportation solution.

Inbolt

Series A in 2024
Inbolt specializes in developing advanced vision systems for industrial robots, aimed at enhancing decision-making capabilities in various environments. By utilizing artificial intelligence and 3D vision, Inbolt's technology provides adaptive real-time guidance for robots, allowing them to operate more intelligently. Additionally, the company's vision-based tools facilitate the automation of complex tasks in unstructured settings, offering real-time quality control for manual operations like torquing, drilling, and riveting. This innovation not only reduces the incidence of faulty operations but also significantly improves overall quality control in industrial processes.

Patrowl

Series A in 2024
Patrowl is a cybersecurity platform designed to enhance the management of external security posture through automated detection and remediation of vulnerabilities. Developed by cybersecurity experts, Patrowl utilizes artificial intelligence to conduct continuous penetration tests, enabling real-time identification of both known and shadow IT assets and their associated vulnerabilities. The platform provides a comprehensive overview of an organization's security status, along with tailored solutions that can be easily accessed and implemented via a user-friendly dashboard. Clients can monitor remediation efforts and verify the effectiveness of fixes with a single click. By streamlining cybersecurity processes, Patrowl aims to empower organizations to elevate their security levels and diminish the threat posed by cybercriminals.

Hepta Medical

Series A in 2024
HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

Enalees

Series A in 2024
Enalees is a biotechnology company focused on developing molecular diagnostic tests specifically for pets. The company has created a platform that enables veterinarians to quickly identify microbes responsible for infectious diseases in leisure animals, such as horses. By providing DNA tests that can detect infections, Enalees facilitates timely diagnosis in veterinary clinics, allowing for more effective treatment of animal pathologies. This innovative approach aims to enhance the veterinary diagnostic process and improve animal health outcomes.

Aura Aero

Grant in 2024
Aura Aero is a manufacturer focused on designing and producing eco-efficient aircraft to support the decarbonization of air transport. The company develops low-carbon vehicles equipped with advanced safety features, including a whole rescue parachute system, anti-crash seats, and anti-crash fuel tanks. Their aircraft are designed with a two-seater configuration and side-by-side taildragger landing gears, aiming to enhance operational efficiency within the aeronautical industry. Through its innovative approach, Aura Aero seeks to contribute significantly to reducing the environmental impact of aviation.

Yumgo

Series A in 2024
Yumgo is a startup focused on creating plant-based egg alternatives designed for baking and cooking. The company develops both white and yellow egg substitutes using natural vegetable proteins, ensuring that the products are free from allergens. Yumgo aims to facilitate a shift toward sustainable dietary choices by offering flavorful options that allow consumers to maintain healthy eating habits without sacrificing taste.

Ray studios

Series A in 2024
Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.

GenoMines

Grant in 2024
Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

Continuity

Series A in 2024
Continuity offers a software-as-a-service (SaaS) platform that utilizes artificial intelligence and open data to identify outdated or invalid insurance contracts. The platform operates across four key product lines: Professional Indemnity, Commercial Property, Construction Workers Insurance, and Directors & Officers Liability. By analyzing data consistently and at scale, Continuity provides insurers with a comprehensive view of small and medium-sized enterprises (SMEs), ensuring that each business is adequately covered throughout its lifecycle. This innovative approach helps to enhance the accuracy and reliability of insurance coverage for SMEs.

LAfricaMobile

Series A in 2024
LAfricaMobile is a digital multichannel cloud communication platform based in Dakar, Senegal, founded in 2014. The company focuses on facilitating communication between enterprises in Africa and their customers, including those in the diaspora. By offering customized mobile marketing solutions that consider the local context, LAfricaMobile enhances the interaction between businesses and their clientele. Its platform specializes in mobile messaging interconnection and integration services, enabling companies to reach a broad audience effectively. This adaptability across multiple operators, channels, and countries ensures that end consumers have instant, secure access to the information they require, thereby strengthening customer relationships in the African market.

Biodol Therapeutics

Grant in 2024
Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

Eyco

Series A in 2024
Eyco specializes in designing and manufacturing smart circuits, playing a significant role in the European microelectronics sector. The company produces hardware components for digital applications, focusing on high-tech solutions that operate with minimal environmental impact. Eyco's commitment to sustainable practices enables clients to implement secure digital applications while promoting environmentally friendly manufacturing processes. Through its advanced industrial machinery, Eyco ensures efficient mass production tailored to client specifications, contributing to the evolving landscape of electronics.

HEPHAISTOS-Pharma

Grant in 2024
Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Magnetfab

Grant in 2024
Magnetfab pioneers the mass-production of integrated micromagnets, driving advanced miniaturization for next-generation consumer electronics, robotics, quantum computing, and beyond.

Touch Sensity

Grant in 2024
Touch Sensity is an information technology company focused on developing sensitivity technology that enhances the interaction between objects and their environments. The company specializes in Internet of Things (IoT) and sensor technologies, creating solutions that can adapt to various sizes, shapes, and surface topologies. Its innovative approach is sensorless and non-invasive, allowing for the comprehensive capture of data related to pressure, extension, and deformation across complete surfaces. This capability enables clients to gain valuable insights by associating physical interactions with environmental factors.

Ascendance

Funding Round in 2024
Founded in 2018 by four ex-Airbus engineers: Jean-Christophe Lambert, Thibault Baldivia, Clément Dinel and Benoît Ferran, Ascendance is an industrial start-up with a mission to decarbonise aviation. Based in the heart of Toulouse, the European capital of aviation, it has developed and markets two products: an innovative hybrid-electric propulsion system ‘Sterna’, and a hybrid-electic vertical take-off and landing (VTOL) aircraft powered by Sterna technology, ‘Atea’.

Tribun Health

Grant in 2024
Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife

Grant in 2024
SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron

Grant in 2024
Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Surge

Grant in 2024
Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Alice & Bob

Grant in 2024
Alice & Bob is a Paris-based company founded in 2020 that specializes in the manufacture of universal, error-free quantum computers. The company's innovative technology features self-correcting superconducting quantum bits, which allow for fault-tolerant quantum computing. This capability enables the execution of any quantum algorithm, thereby assisting industries and researchers in addressing complex challenges across various fields. By focusing on developing advanced quantum computing solutions, Alice & Bob aims to facilitate breakthroughs in solving significant problems in quantum research and industry applications.

Sequans Communications

Grant in 2024
Sequans Communications S.A. is a designer and supplier of cellular semiconductor solutions, specializing in 4G and 5G chips and modules tailored for massive, broadband, and critical Internet of Things (IoT) markets. Established in 2003 and headquartered in Paris, France, the company offers a diverse product portfolio that includes its Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms for 5G/4G massive IoT applications, known for their low power consumption and integrated functionalities. For broadband and critical IoT applications, Sequans provides the Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, which are optimized for various sectors including residential, enterprise, and industrial uses. The company serves a global market with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China.

ABIONYX Pharma

Grant in 2024
ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Sunver

Grant in 2024
Sunver is a start-up offering the first fully plug & play B2B SaaS solution for tourism establishments and restaurants, enabling them to create and configure a Guest App in just a few minutes.

Hawkcell

Series A in 2024
HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

UniFox

Grant in 2024
UniFox is an AI-driven ecosystem focused on sustainable investment, integrating green energy and eco-responsible technologies for individual and institutional investors. Its structure encompasses four divisions: B2C, B2B, Capital Ventures, and Green DeFi. Central to its offerings is VulpesAI, a multi-modal AI engine that employs market data, sentiment analysis, and ESG (Environmental, Social, Governance) criteria to create optimized investment strategies while operating on renewable energy sources. For individual users, UniFox provides AI-powered portfolio management that delivers comprehensive market insights and risk management, allowing for personalized investment strategies. On the institutional side, it offers advanced data access and metrics for large-scale investments in green projects. The Green DeFi division focuses on financing eco-friendly technology initiatives through decentralized finance, utilizing eco-taxed products and tokens to support sustainable ventures. Overall, UniFox seeks to enhance the accessibility of investment opportunities while promoting environmental responsibility and addressing challenges faced by novice traders in the market.

Groover

Series A in 2024
Groover is an innovative platform designed specifically for independent artists, focusing on music promotion and discovery. It has cultivated a community of 200,000 artists across more than 186 countries. The platform allows musicians to directly submit their music to media outlets, radio stations, playlists, and record labels, ensuring they receive valuable feedback from a vetted network of 3,000 music curators and professionals. With over two million feedback interactions on tracks, Groover provides artists with the opportunity to obtain honest insights and tangible sharing proposals, facilitating their growth and visibility in the competitive music industry.

Agrilife Studio

Series A in 2024
Agrilife Studio is a startup studio that specializes in agriculture and environmental solutions. It aims to enhance the efficiency and productivity of farming through agri-tech innovations. The studio offers a comprehensive suite of tools and resources designed for farmers, which includes data analytics, precision agriculture tools, and improved market access. By providing these resources, Agrilife Studio enables farmers to make informed decisions regarding their crops and livestock while facilitating easier connections with potential buyers.

Greenerwave

Series A in 2024
Greenerwave is a company focused on enhancing wireless indoor connectivity through innovative technology. It has developed electronically reconfigurable surfaces that function as electromagnetic mirrors, which address connectivity and mobility challenges. This technology enables the creation of cost-effective and energy-efficient beamforming antennas and radars. By improving indoor wireless signals, Greenerwave aims to ensure that customers consistently experience reliable connectivity, thereby transforming how people interact with wireless networks.

Panopli

Series A in 2024
Panopli is an online platform based in Saint-Ouen, France, that specializes in the customization and management of personalized gifts and team apparel. Founded in 2017, the company offers a range of artistic items, including clothing such as t-shirts and sweaters, as well as decorative pieces like art posters and drawings. Panopli's service simplifies the gifting process by allowing customers to browse and purchase unique items, which are then shipped directly to the recipient. The platform also provides order tracking and inventory management, ensuring a seamless experience for users looking to send thoughtful gifts without the hassle of traditional gifting methods.

AQEMIA

Series A in 2024
AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Aldoria

Series A in 2024
Aldoria specializes in space situational awareness, focusing on the collection, processing, and utilization of data to protect critical assets in space. The company addresses the growing challenges of space sustainability caused by increasing amounts of space debris and traffic. Its services encompass the detection, tracking, cataloging, and risk assessment of artificial satellites and space debris. By actively monitoring these elements, Aldoria helps operators and space organizations avoid potential hazards and adjust orbital paths, ultimately contributing to safer and more sustainable space operations. The company also provides users with a modern situational awareness platform and detailed sustainability reports.

Temo

Series A in 2024
Temo specializes in the manufacturing of portable electric motors designed for small watercraft, including dinghies, sailing boats, and rowboats. The company's products are characterized by their lightweight design and ease of installation, allowing users to enhance their boating experience with efficient outboard electric propulsion systems. By focusing on user-friendly solutions, Temo aims to meet the needs of recreational boaters seeking reliable and convenient alternatives to traditional motor systems.

I.Ceram

Grant in 2024
I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Neocem

Venture Round in 2024
Neocem is a manufacturer focused on producing low-carbon cements for the construction industry. The company has developed an innovative process that allows for the use of raw materials sourced from recovery sectors. By utilizing calcined flash clays, Neocem creates and promotes a range of environmentally friendly binders designed to reduce the carbon footprint associated with traditional cement production.

Novacium

Grant in 2023
Novacium operates as an innovative start-up that specializes in the next generation material development.

Okomera

Grant in 2023
Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Huvy

Grant in 2023
Huvy specializes in developing a skin cancer screening application that utilizes artificial intelligence to enhance dermatological treatment pathways. The application aims to identify cancer risks and provide essential medical information in real-time. By facilitating dermatological screening, Huvy's technology enables access to initial diagnostic orientation for populations in areas with limited medical resources. This approach allows for timely care and intervention when there is a suspicion of skin cancer, ultimately improving health outcomes for underserved communities.

EYEGAUGE

Grant in 2023
eyeGauge is a Paris-based deep tech start-up dedicated to transforming the maritime industry by facilitating the decarbonization of maritime transportation. The company aims to help shipping companies meet International Maritime Organization targets by reducing greenhouse gas emissions by at least 50% by 2050. To comply with decarbonization regulations, ship owners must accurately measure and report emissions after every voyage. However, 85% of the world's fleet currently relies on manual data collection, which is often unreliable and difficult to analyze. eyeGauge addresses this challenge by offering an innovative, automated solution that collects data from onboard systems in a contactless and non-invasive manner. This technology generates consistent and comparable data, creating a digital model of a vessel's equipment and machinery. By providing insights into operations, eyeGauge enables shipping companies to identify optimization opportunities and enhance efficiency, ultimately supporting their efforts to reduce emissions and comply with regulations.

Prove & Run

Series A in 2023
Prove & Run has been created with the idea that large scale deployment of connected objects will become a target for remote cyber-attacks and that the technologies in use in the mobile industry were insufficient to answer to the challenge. When designing connected objects, security engineers can in effect rely on three pillars: (1) Secure elements or hardware coprocessors; (2) Trusted Execution Environment (TEE) or secure OSs; (3) Hardware - or software-based hypervisors. In order to resist to sophisticated remote attacks, the last two need to be formally proven so as to be as close as possible to zero-bugs. This is what we have done at Prove & Run with ProvenCore, a formally proven secure OS and ProvenVisor a next generation secure hypervisor. In most cases using of single instance of ProvenCore on a given connected object will be sufficient to protect against hackers with multi-million dollar budgets.

Astraveus

Grant in 2023
Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Poppins

Venture Round in 2023
Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Injectpower

Grant in 2023
Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.

Hughy

Grant in 2023
F&B advertising webapp

Albert

Venture Round in 2023
Albert is a software company that provides a SaaS platform. The company was founded in 2018 and is based in Paris, France.

Spark Cleantech

Grant in 2023
Spark Cleantech is a pioneering company developing a plasma technology to convert greenhouse gases into hydrogen fuel. Its core process, called plasmolysis, uses cold pulsed plasma discharges to break down methane or carbon dioxide and methane mixtures, producing hydrogen, solid carbon, and carbon monoxide. This on-site hydrogen production offers a competitive, carbon-neutral alternative to fossil fuels, enabling the decarbonization of industrial heat and the transition to clean transportation.

Mecaware

Series A in 2023
MECAWARE specializes in battery recycling technology aimed at recovering critical metals and rare earth elements, thus supporting the sustainable supply chain for the battery sector. The company focuses on resource circularity and enhancing strategic autonomy through innovative solutions that promote eco-efficient industrial practices. By providing services for recycling critical metals from end-of-life batteries and production scraps, MECAWARE helps its customers secure their supply of essential materials while minimizing environmental impact.

Global Bioenergies

Grant in 2023
Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Niryo

Series A in 2023
Niryo is a manufacturer of educational robots designed to facilitate learning in robotics and computer programming. The company specializes in open-source six-axis collaborative tools, which are utilized by educational institutions to enhance higher education and provide professional training. These robots are particularly valuable for prototype industrial case studies, allowing users to engage in hands-on learning experiences that bridge the gap between theoretical knowledge and practical application. By focusing on educational solutions, Niryo aims to advance the understanding and skills necessary for the future of technology and automation.

Circul'Egg

Grant in 2023
Circul'Egg specializes in recycling eggshells from various companies, converting them into two primary products: calcium carbonate powder and shell membrane powder. By promoting sustainable practices within the circular economy, Circul'Egg addresses the growing demand for eco-friendly ingredients in the animal feed, nutraceutical, and cosmetics markets. Its offerings are designed to meet the needs of various stakeholders, including those in pet food, farm animal feed, dietary supplements, and cosmetic industries. The company emphasizes the natural, biobased, and vegetarian aspects of its products, ensuring they are both environmentally friendly and rich in valuable minerals and biomolecules. Established in Paris, Ile-de-France, France, Circul'Egg plays a crucial role in transforming waste into valuable resources for multiple sectors.

Umiami

Series A in 2023
Umiami is a French food-tech startup founded in 2020 and based in Paris, focused on developing plant-based food technology aimed at reducing meat consumption. The company specializes in creating plant-based whole-cuts that utilize plant proteins, providing consumers with alternatives that closely replicate the taste, texture, and aroma of traditional meat products. By offering these innovative solutions, Umiami seeks to address the growing demand for sustainable food options while promoting healthier dietary choices.

Remixt

Grant in 2023
Remixt is a leading Diversity, Equity and Inclusion tech platform dedicated to preventing key HR risks caused by harassment and discrimination. The company is headquartered in Paris, France, with employees in Paris, San Francisco, Toulouse and Annecy. Remixt’s clients include global corporations Heineken, Société Générale, Accenture, Groupe BPCE-Natixis and Hexagon. For more information: http://www.remixt.co

Eramet

Grant in 2023
ERAMET is a world leader in alloy metals, including manganese and nickel, and high-end metallurgy. ERAMET also develops activities with high growth potential, such as mineralized sands (titanium dioxide and zircon), lithium and recycling. The Group employs approximately 13,000 people in 20 countries.

Toopi Organics

Grant in 2023
Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.

Teale

Series A in 2023
Teale is a digital mental health platform that integrates psychology and technology to enhance mental well-being. The platform offers personalized and interactive digital healthcare solutions, enabling individuals to manage their mental health effectively. Teale also conducts collective workshops tailored to specific needs within workplaces, fostering a supportive environment for mental health initiatives. Through its curated network of mental health experts, Teale provides individual support and personalized digital programs, allowing users to monitor and improve their psychological resilience. This approach not only benefits individuals but also contributes to sustainable growth for organizations.

Dattak

Series A in 2023
Dattak specializes in providing cyber insurance solutions that leverage advanced cybersecurity technologies. By utilizing these tools, Dattak enables businesses to assess their cybersecurity posture without the need for complex questionnaires. The company focuses on serving insurance brokers and clients, including veterinary specialists, emergency services, and small to medium-sized enterprises, by offering tailored cyber insurance options. Dattak's approach not only helps clients secure insurance coverage but also equips them with resources to effectively prevent and defend against cyberattacks, thereby reducing overall risk.

Phagos

Grant in 2023
Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Mob-Energy

Series A in 2023
Mob-Energy is a privately held company founded in 2018 and based in Villeurbanne, Auvergne-Rhône-Alpes. The company specializes in developing innovative mobile charging solutions for electric vehicles. Its autonomous charging robots are designed to optimize existing infrastructure by storing energy in second-life batteries installed in parking facilities. These robots can autonomously move to vehicles that request a charge, providing a convenient and efficient way for clients to power their parked cars. Through its technology, Mob-Energy aims to enhance the accessibility and usability of electric vehicle charging systems.

Aviwell

Grant in 2023
Aviwell is focused on creating healthy, natural, and sustainable solutions aimed at enhancing animal health and growth, thereby contributing to global nourishment. The company operates a microbiota-based discovery platform that leverages artificial intelligence and machine learning to bridge digital and life sciences. By developing innovative food products, Aviwell seeks to provide valuable insights into animal health, growth, and performance, ultimately supporting the agri-food industry in its efforts to sustainably meet the needs of a growing population.

SFE PROCESS

Series A in 2023
SFE Process specializes in the design and manufacture of laboratory equipment, particularly focusing on extraction machines that utilize supercritical fluids. The company develops innovative and modular pressure equipment, providing tailored laboratory systems that cater to a variety of applications. By offering flexible and multipurpose extraction systems, SFE Process enables its clients to efficiently achieve their objectives in diverse research and industrial settings.

Santexpat.fr

Series A in 2023
Santexpat is a health insurance platform tailored for French expatriates, operating in over 200 countries. Established in 2020 and headquartered in Paris, it provides users with the ability to analyze more than 100 health insurance options and subscribe directly online. The platform displays insurer prices aligned with public rates, ensuring transparency by including all costs without additional fees. Users can manage their insurance premiums directly through the site of their chosen insurer. Additionally, Santexpat offers 24/7 teleconsultations with French-speaking doctors, enhancing access to healthcare for expatriates.

Cleyrop

Series A in 2023
Cleyrop provides a secure data hub that simplifies access and enhances the use of data for its clients. The company offers a comprehensive portal and a scalable application suite designed to ingest, store, process, exploit, and visualize data efficiently. Key features include collaborative workspaces, management of access rights and security, and oversight of storage and computing infrastructures. Additionally, Cleyrop enables the deployment and orchestration of data pipelines, as well as the viewing and sharing of data stories. This suite empowers clients to govern, catalog, supervise, and monitor their data assets in a secure and industrial environment, ensuring effective data management and accessibility.

Santé Académie

Series A in 2023
Santé Académie is an online training platform focused on providing continuous medical education to healthcare professionals. Recognizing the evolving roles of caregivers and the rapid obsolescence of medical knowledge, the platform offers high-quality educational videos tailored to the schedules of busy professionals. Each course is divided into short episodes ranging from 5 to 15 minutes, allowing doctors, nurses, pharmacists, and care assistants to learn at their own pace. The courses cover clinical and regulatory topics and are certified by the ANDPC, produced by experts from prestigious institutions. With the aim of enhancing patient care and engagement, Santé Académie has already gained approval from over 20,000 professionals and health institutions, making advanced medical knowledge accessible directly from mobile devices.

Deemea

Grant in 2023
Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.

EyeLights

Series A in 2023
EyeLights specializes in innovative motorcycle accessories by offering a Head Up Display GPS that enhances rider safety and experience. This device projects crucial navigation and safety information directly into the rider's line of sight, allowing them to maintain focus on the road. It alerts users to potential hazards such as dangerous bends, nearby obstacles, and speed limit violations. Designed for quick installation on various types of helmets, the EyeLights product can be set up in under five minutes. Its compact optical technology ensures visibility of GPS data from over two meters away and supports audio functions for up to eight hours. The device is adaptable to sun visors, resistant to rain and fog, and lightweight, weighing less than 100 grams, making it a practical choice for motorcycle enthusiasts seeking enhanced situational awareness while riding.

Pricemoov

Series A in 2023
Pricemoov, established in 2016 and headquartered in Paris, France, specializes in price management and optimization. It offers an online platform that leverages data science and automation to analyze sales history and current demand, enabling businesses to set optimal prices for their products or services. The platform caters to both B2B and B2C companies, helping them adapt to market dynamics, empower sales teams, and ultimately unlock revenue potential.

Kiro

Series A in 2023
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

XXII

Series A in 2023
XXII is a technology company with over 50 employees that specializes in the design, development, and marketing of a SaaS platform known as XXIICORE. This platform is focused on deploying and configuring algorithms specifically for video stream analysis. XXII's solution has gained traction among various sectors and local authorities, enabling users to leverage video analysis to enhance operational performance. Clients benefit from the ability to create new tools and applications using the company’s algorithms, which facilitate real-time video analysis and offer measurable advantages in their operations.

GenoMines

Grant in 2023
Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

Kovalee

Series A in 2023
Kovalee is a mobile app publisher that supports app creators by providing a comprehensive application publishing platform. The company partners with app owners to elevate their apps in the marketplace, offering services such as product enhancement, user acquisition, monetization, and app store optimization. Kovalee's platform features modular design and application testing, enabling developers to focus on content and code while leveraging data-driven strategies. Additionally, the company employs artificial intelligence to predict customer behavior, helping developers optimize their apps for better performance and profitability.

AlgoTherapeutix

Grant in 2023
AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Pili

Series A in 2023
PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

Oneleaf

Grant in 2023
Oneleaf is a startup focused on making hypnosis more accessible to individuals seeking personal improvement. The company has developed a self-hypnosis app that offers various programs aimed at addressing issues such as smoking cessation, anxiety reduction, and weight loss. By providing expert-guided digital resources, Oneleaf aims to assist users in overcoming detrimental habits and enhancing their overall well-being. The overarching goal of the company is to empower a billion people to achieve their best selves through self-hypnosis.

NFL Biosciences

Grant in 2023
NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Miraxess

Venture Round in 2023
Miraxess specializes in transforming smartphones into functional laptops through its innovative product, the Mirabook. Recognizing the growing reliance on smartphones for personal and professional tasks, the company has developed a plug-in device that enhances the capabilities of mobile phones, effectively creating a full-fledged laptop experience. This solution aims to improve productivity and comfort, catering to the needs of users for both work and entertainment. By leveraging the existing power of smartphones, Miraxess offers a practical convergence of mobile and computing technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.